Active Ingredient History
Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis, and other aspects of tumor biology. Hence, it is under investigation for the treatment of glioblastoma, where it may act by inhibiting angiogenesis, and influencing tumor invasion and proliferation. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 1)
Breast Neoplasms, Male (Phase 1)
Burkitt Lymphoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Choroid Plexus Neoplasms (Phase 1)
Craniopharyngioma (Phase 1)
Diffuse Intrinsic Pontine Glioma (Phase 1)
DNA Mismatch Repair (Phase 1)
Ependymoma (Phase 1)
Glioblastoma (Phase 3)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hodgkin Disease (Phase 1)
Intestinal Neoplasms (Phase 1)
Intraocular Lymphoma (Phase 1)
Kidney Failure, Chronic (Phase 1)
Leukemia (Phase 2)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia-Lymphoma, Adult T-Cell (Phase 1)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lung Neoplasms (Phase 1)
Lymphoma (Phase 1)
Lymphoma, AIDS-Related (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 1)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, T-Cell (Phase 1)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 1)
Multiple Myeloma (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Myeloproliferative Disorders (Phase 1)
Neoplasms (Phase 1)
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neoplasms, Squamous Cell (Phase 1/Phase 2)
Neuroectodermal Tumors (Phase 1)
Oligodendroglioma (Phase 2)
Precancerous Conditions (Phase 1)
Sarcoma (Phase 1)
Sezary Syndrome (Phase 1)
Small Cell Lung Carcinoma (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue